» Articles » PMID: 16545950

The Distance-saturation Product Predicts Mortality in Idiopathic Pulmonary Fibrosis

Overview
Journal Respir Med
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2006 Mar 21
PMID 16545950
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The 6-min walk test (6MWT) has prognostic value in various pulmonary disorders including idiopathic pulmonary fibrosis (IPF). We determined the individual prognostic accuracy of distance walked and oxygen saturation during the 6MWT in patients with IPF. We defined a new composite index, the distance-saturation product (DSP), which is the product of distance walked and lowest oxygen saturation during the 6-min walk test. We compared the performance of the DSP to the individual 6MWT parameters in predicting mortality.

Methods: We evaluated pulmonary function tests, 6-min walk parameters and the DSP between survivors and non-survivors. The ability of each measure to discriminate outcomes was determined by receiver operator curves.

Results: 81 patients (48 survivors, 33 non-survivors) were included. Pulmonary function tests were similar and did not correlate with survival. Desaturation was greater (89.4% versus 83.7%, P<0.001) and distance walked was lower (406.9 versus 181.3m, P = 0.005) in non-survivors. The DSP was significantly lower among non-survivors (364.8 versus 153.5m%, P < 0.001) and predicted mortality more accurately than either individual 6MWT component (P = 0.035 versus desaturation, P=0.040 versus distance). A DSP <200 m% was associated with a seven-fold greater risk of 12-month mortality and an 18.0% shorter median survival compared with a DSP > 200 m% (P < 0.001).

Discussion: Each component of the 6-min walk independently predicted mortality in IPF with greater accuracy than spirometry. However, a composite of both parameters, the DSP, provides slightly greater accuracy and represents a novel measure for assessing survival in patients with IPF.

Citing Articles

Comparative Analysis of Submaximal and Maximal Effort Capacities in Patients Post-COVID-19 and Individuals with Chronic Restrictive Lung Diseases.

Rosa K, de Melo F, Riscado F, Oliveira R, Oliveira D, Oliveira-Silva I Int J Environ Res Public Health. 2025; 22(2).

PMID: 40003486 PMC: 11855376. DOI: 10.3390/ijerph22020261.


Clinimetric properties of field exercise tests in cystic fibrosis: a systematic review.

Corda J, Holland A, Tannenbaum E, Cox N Eur Respir Rev. 2024; 33(174).

PMID: 39694588 PMC: 11653197. DOI: 10.1183/16000617.0142-2024.


Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH-CLD): A consensus statement from the pulmonary vascular research institute's innovative drug development initiative-group 3 pulmonary hypertension.

Vitulo P, Piccari L, Wort S, Shlobin O, Kovacs G, Vizza C Pulm Circ. 2024; 14(4):e70005.

PMID: 39659477 PMC: 11629413. DOI: 10.1002/pul2.70005.


The Management of Interstitial Lung Disease in the ICU: A Comprehensive Review.

Dhanani Z, Gupta R J Clin Med. 2024; 13(22).

PMID: 39597801 PMC: 11595168. DOI: 10.3390/jcm13226657.


Evaluation of preoperative cardiopulmonary reserve and surgical risk of patients undergoing lung cancer resection.

Petrella F, Cara A, Cassina E, Faverio P, Franco G, Libretti L Ther Adv Respir Dis. 2024; 18:17534666241292488.

PMID: 39455414 PMC: 11523151. DOI: 10.1177/17534666241292488.